Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy (Q37866150)

24 August 2017

1 reference

title

Anti-cancer immune response mechanisms in neoadjuvant and targeted therapy (English)

1 reference

24 August 2017

3

Sibylle Loibl

0 references

Silvia Darb-Esfahani

2

object named as

Silvia Darb-Esfahani

0 references

Korinna Jöhrens

5

object named as

Korinna Jöhrens

0 references

author name string

Carsten Denkert

1

1 reference

PubMed ID

21499853

24 August 2017

Ioannis Anagnostopoulos

4

1 reference

PubMed ID

21499853

24 August 2017

language of work or name

1 reference

17 April 2011

1 reference

Seminars in Immunopathology

24 August 2017

1 reference

24 August 2017

33

1 reference

24 August 2017

4

1 reference

24 August 2017

341-351

1 reference

https://scigraph.springernature.com/pub.10.1007/s00281-011-0261-0

24 August 2017

0 references

cites work

HER2-targeted therapy in breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Resistance to Trastuzumab in Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Breast tumor cells isolated from in vitro resistance to trastuzumab remain sensitive to trastuzumab anti-tumor effects in vivo and to ADCC killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Cell surface antigen and molecular targeting in the treatment of hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Effector memory T cells, early metastasis, and survival in colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The immune response against dying tumor cells: avoid disaster, achieve cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Molecular interactions between dying tumor cells and the innate immune system determine the efficacy of conventional anticancer therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Immunological aspects of cancer chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The anticancer immune response: indispensable for therapeutic success?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Tumor-infiltrating lymphocytes predict response to neoadjuvant chemotherapy in patients with breast carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Regulatory T cells in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

An inflammation-based prognostic score and its role in the nutrition-based management of patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic and macrophage infiltration, microvessel density and survival in patients with primary operable breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The relationship between tumour T-lymphocyte infiltration, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Interleukin-2 enhances the natural killer cell response to Herceptin-coated Her2/neu-positive breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

IL-12 enhances the natural killer cell cytokine response to Ab-coated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Correlation between NK function and response to trastuzumab in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Trastuzumab mediated T-cell response against HER-2/neu overexpressing esophageal adenocarcinoma depends on intact antigen processing machinery.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Dendritic cell interactions with NK cells from different tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Antigen-processing machinery in human dendritic cells: up-regulation by maturation and down-regulation by tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The effects of trastuzumab on the CD4+CD25+FoxP3+ and CD4+IL17A+ T-cell axis in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The story of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The biology of chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Chronic myelogenous leukemia: biology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Dasatinib, a small-molecule protein tyrosine kinase inhibitor, inhibits T-cell activation and proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Immunosuppression and atypical infections in CML patients treated with dasatinib at 140 mg daily

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Rituximab inhibits B-cell receptor signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Novel human transitional B cell populations revealed by B cell depletion therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The CD52 antigen and development of the CAMPATH antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Rediscovering alemtuzumab: current and emerging therapeutic roles

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Alemtuzumab induces caspase-independent cell death in human chronic lymphocytic leukemia cells through a lipid raft-dependent mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Investigation of the mechanism of action of alemtuzumab in a human CD52 transgenic mouse model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00281-011-0261-0

Effect of Campath-1H antibody on human hematopoietic progenitors in vitro

21 January 2018

1 reference

12 December 2020

Antihuman epidermal growth factor receptor 2 (HER2) monoclonal antibody trastuzumab enhances cytolytic activity of class I-restricted HER2-specific T lymphocytes against HER2-overexpressing tumor cells

1 reference

12 December 2020

Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes

1 reference

12 December 2020

Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H)

1 reference

12 December 2020

The humoral immune system has a key prognostic impact in node-negative breast cancer

1 reference

12 December 2020

CD4+CD25+ regulatory T-cell frequency in HER-2/neu (HER)-positive and HER-negative advanced-stage breast cancer patients

1 reference

12 December 2020

Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab

1 reference

12 December 2020

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

12 December 2020

Do autoantigens define autoimmunity or vice versa?

1 reference

12 December 2020

Prospects of controlling breast cancer metastasis by immune intervention

1 reference

12 December 2020

The relationship between the local and systemic inflammatory responses and survival in patients undergoing resection for localized renal cancer

1 reference

12 December 2020

Lymphocyte infiltrates as a prognostic variable in female breast cancer

1 reference

12 December 2020

Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy

1 reference

12 December 2020

1 reference

12 December 2020

Pathologic Complete Response to Neoadjuvant Chemotherapy of Breast Carcinoma Is Associated with the Disappearance of Tumor-Infiltrating Foxp3+ Regulatory T Cells

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Pilot Study of the Mechanism of Action of Preoperative Trastuzumab in Patients with Primary Operable Breast Tumors Overexpressing HER2

1 reference

12 December 2020

Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils

1 reference

12 December 2020

Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H

1 reference

12 December 2020

Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer

1 reference

12 December 2020

Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma

1 reference

12 December 2020

Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer

1 reference

12 December 2020

Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer.

1 reference

12 December 2020

10.1007/S00281-011-0261-0

Identifiers

DOI

1 reference

24 August 2017

1 reference

PubMed ID

21499853